These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

972 related articles for article (PubMed ID: 23742877)

  • 1. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
    Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
    Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
    Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
    Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
    Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
    Fizazi K; Scher HI; Molina A; Logothetis CJ; Chi KN; Jones RJ; Staffurth JN; North S; Vogelzang NJ; Saad F; Mainwaring P; Harland S; Goodman OB; Sternberg CN; Li JH; Kheoh T; Haqq CM; de Bono JS;
    Lancet Oncol; 2012 Oct; 13(10):983-92. PubMed ID: 22995653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
    Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
    Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Gotlieb WH; Amant F; Advani S; Goswami C; Hirte H; Provencher D; Somani N; Yamada SD; Tamby JF; Vergote I
    Lancet Oncol; 2012 Feb; 13(2):154-62. PubMed ID: 22192729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
    Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
    Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
    J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
    Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
    Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
    Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
    Chi KN; Higano CS; Blumenstein B; Ferrero JM; Reeves J; Feyerabend S; Gravis G; Merseburger AS; Stenzl A; Bergman AM; Mukherjee SD; Zalewski P; Saad F; Jacobs C; Gleave M; de Bono JS
    Lancet Oncol; 2017 Apr; 18(4):473-485. PubMed ID: 28283282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.